Vyome Holdings, Inc. — requested filing and issuer mismatch
Important: The supplied Form 10-Q is for Obalon Therapeutics, Inc., not Vyome Holdings, Inc. The summary below covers Obalon’s filing; verify the issuer before relying on it.
Business context and reporting period
This unaudited quarterly report covers the three and six months ended June 30, 2019. Obalon developed and commercialized the FDA-approved Obalon Balloon System for weight loss. In April 2019, it eliminated its field sales force and shifted toward centralized physician support and planned company-owned or managed retail centers.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $0.4 million | $2.7 million | $2.2 million | $4.1 million |
| Gross profit (loss) | $(0.3) million | $1.0 million | $0.3 million | $1.6 million |
| Operating expenses | $6.1 million | $10.6 million | $14.8 million | $23.2 million |
| Net loss | $(6.8) million | $(9.8) million | $(15.1) million | $(21.9) million |
| Net loss per share | $(0.25) | $(0.57) | $(0.60) | $(1.29) |
- Q2 gross margin was approximately negative 76%, versus approximately 37% a year earlier. First-half gross margin was 12%, down from 39%.
- First-half operating cash use was $14.0 million, compared with $18.7 million in 2018. Investing activities provided $2.5 million; financing activities provided $3.8 million. Cash declined by $7.7 million over the half-year.
- At June 30, cash and cash equivalents were $13.5 million, with no short-term investments. The lender required cash balances at least equal to the $5.0 million outstanding loan, effectively leaving $8.5 million accessible under that covenant. The filing states substantial doubt exists about the company’s ability to continue as a going concern.
- Total assets were $19.2 million, current liabilities $10.1 million, and stockholders’ equity $8.4 million. The entire $5.0 million loan was classified as current. The loan bore a 7.0% variable rate and matured in July 2022; principal payments were scheduled to begin in August 2019.
Material changes versus the prior comparable period
- Q2 revenue fell $2.3 million, primarily from $1.2 million lower Middle East distributor sales and $1.1 million lower U.S. sales. First-half revenue declined $1.9 million, including a $1.4 million decrease in distributor sales.
- Q2 gross profit moved to a deficit, reflecting lower revenue, an inventory write-down tied to discontinuation of the prior-generation system, and continuing fixed manufacturing costs.
- Operating expenses fell substantially following reduced headcount and lower marketing spending. First-half R&D declined to $4.2 million from $6.0 million, and SG&A to $10.5 million from $17.3 million. Q2 included $1.1 million of restructuring charges.
- Interest expense increased to $0.3 million for Q2 and $0.5 million for the first half, reflecting the earlier $10.0 million loan draw and higher rates.
- Common shares outstanding increased to 35.6 million from 23.5 million at year-end 2018. The company reported $8.8 million net proceeds from common-stock issuance in first-half financing cash flows, including proceeds from multiple equity financing channels.
Outlook, management commentary, and key risks
- Management expected SG&A to decline beginning in Q3 due to workforce reductions. It planned to open its first Obalon-branded retail center before year-end 2019, but stated that the new model was untested and its success could not be predicted. A San Diego office lease for a retail center was signed in July 2019.
- Management said near-term operations depended on raising capital or completing a strategic alternative. It warned that if these were not achieved before cash fell below $5.0 million, the company could default on its cash covenant and might need to accelerate strategic alternatives, including possible bankruptcy protection.
- Financing included a May 2019 sale of 5.0 million shares at $0.60 per share for $3.0 million gross proceeds, an ATM facility, and a Lincoln Park purchase agreement. Access to further proceeds was uncertain and subject to market-price, exchange-cap, and other limits. The company said no future Lincoln Park issuances were anticipated.
- Major risks included severe liquidity constraints and going-concern uncertainty; declining sales and dependence on a single product; execution risk in the retail-center strategy; customer and supplier concentration; manufacturing and quality challenges; medical-device safety, regulatory, and clinical-study requirements; and potential equity dilution.
- A shareholder class-action lawsuit remained pending; the company considered it without merit. A motion-to-dismiss hearing was scheduled for August 1, 2019. The company also disclosed Nasdaq deficiencies relating to stockholders’ equity and minimum bid price, with stated compliance deadlines in November 2019.
- Subsequent to quarter-end, stockholders approved and the board authorized a 1-for-10 reverse stock split; the filing said the amendment had not yet been filed as of the financial-statement date. The company also disclosed July grants of stock options and restricted stock units.
Important facts for investors to verify
- Confirm the issuer: the supplied filing names Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Verify current unrestricted cash, cash-covenant compliance, debt repayment status, and the company’s ability to fund operations.
- Check whether additional financing or a strategic transaction was completed, and assess the resulting dilution and liquidity.
- Confirm whether the planned retail center opened and whether the new commercialization model generated revenue.
- Review subsequent Nasdaq listing compliance, the reverse stock split, the shareholder litigation, and post-approval study status.